ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/DNA-methyltransferase
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/DNA-methyltransferase
28
trial(s) found.
NCT07007312
Haem
Phase 3
Recruiting
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (
KO-MEN-017
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06852222
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy (
cAMeLot-2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
KMT2A inhibitor
antimetabolite
placebo
Leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06765109
Advanced
Phase 3
Recruiting
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (
ALKAZAR
)
ALK/RET inhibitor
ALK inhibitor,fourth generation
ALK inhibitor,second generation
+ DNA methyltransferase inhibitor
Lymphoma
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06656494
Haem
Phase 1
Recruiting
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies. (
ICP-CL-01205
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Leukaemia
Myelodysplastic syndrome
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06652438
Haem
Phase 3
Recruiting
Randomized Study to Assess Revumenib in Combination With Azacitidine + Venetoclax in Adult Patients With Newly Diagnosed NPM1-mutated or KMT2A-rearranged AML Ineligible for Intensive Chemotherapy (
HO177
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
Acute myeloid leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT06651229
Haem
Phase 1
Recruiting
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (
90189892AML1001
)
unknown drug class
+ DNA methyltransferase inhibitor
Cancer
Leukaemia
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06372717
Haem
Phase 1
Recruiting
A Phase 1 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and in Combination With Azacitidine and in Combination With Azacitidine Plus Venetoclax in Adults With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Hollywood Private Hospital
NCT05907057
Haem
Phase 3
Recruiting
A Single Arm, Open-label Phase 3b Study to Describe the Safety and Tolerability of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy (
DIM-95031-006
)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Acute myeloid leukaemia
NCT05756322
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias (
LBS-007-CT01
)
CDC7 inhibitor
+ DNA methyltransferase inhibitor
Leukaemia
NSW
2500 - Wollongong - Wollongong Private Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Hollywood Private Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05636514
Haem
Phase 1
Recruiting
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia (
CELESTIAL-MDS
)
DNA methyltransferase inhibitor
FAK inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
NCT05183035
Paed
Phase 3
Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (
ITCC-101-APAL2020D
)
Bcl2 inhibitor
anti-CD33 antibody-drug conjugate
antimetabolite
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT04771130
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies (
BGB-11417-103
)
Bcl2 inhibitor
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6009 - Nedlands - One Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04581512
Haem
Phase 1 / Phase 2
Recruiting
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies (
EP0042-101
)
FLT3/Aurora inhibitor
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
WA
6000 - Perth - Royal Perth Hospital
NCT03850574
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (
TUSCANY
)
FLT3 inhibitor
+ DNA methyltransferase inhibitor
Chronic myelomonocytic leukaemia
Leukaemia
Myelodysplastic syndrome
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4812 - Townsville - Townsville University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12626000278336
Haem
Not Applicable
Not yet recruiting
ALLG AMLM28-A3. A randomised study of ambulatory management compared to standard of care for fever related hospitalisation in patients with AML receiving Venetoclax and Azacitidine – a domain of Achieving Durable remissions via Adaptive Pro-survival Targeting in AML (ADAPT) (
ADAPT-ID
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
ACTRN12625000994482
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (
ADAPT-A2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000964415
Haem
Phase 3
Not yet recruiting
ALLG AMLM30/EVOLVE II: Randomised study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy (
EVOLVE-II
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
menin-MLL1 inhibitor
Acute myeloid leukaemia
Cancer
ACTRN12625000201471
Haem
Phase 1 / Phase 2
Recruiting
ALLG MDS05 (MYDAS-T)/D3 (MESSAGE): Myelodysplasia Advancing Strategies in Therapy platform trial - Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement (
MDS05-D3
)
Cedazuridine
DNA methyltransferase inhibitor
Decitabine
Sturlimogene Erparepvec
bispecific-EGFR/CDH17 antibody-drug conjugate
cancer therapy
cancer therapy,DNA methyltransferase-targeting
cancer therapy,cytidine deaminase-targeting
cytidine deaminase inhibitor
oncolytic herpes simplex virus
unknown drug class
+ DNA methyltransferase inhibitor
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12624000738527
Haem
Phase 2
Recruiting
AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy. (
AMLM22-D4-CADENCE
)
DNA methyltransferase inhibitor
antimetabolite
vaccine therapy,dendritic cell
Acute myeloid leukaemia
ACTRN12624000065594
Haem
Not Applicable
Not yet recruiting
ALLG AMLM28/STOP: Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) (ADAPT): The ADAPT Platform trial - STOP Domain
Azacitidine
Bcl2 inhibitor
DNA methyltransferase inhibitor
Venetoclax
antimetabolite
cancer therapy
cancer therapy,Bcl2-targeting
cancer therapy,DNA methyltransferase-targeting
cytotoxic chemotherapy
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
ACTRN12623000900617
Haem
Phase 2
Recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12622001302741
Haem
Phase 1 / Phase 2
Not yet recruiting
MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (
ALLG
)
BRD4 inhibitor
cytidine deaminase inhibitor
+ DNA methyltransferase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
ACTRN12621001265864
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (
AMLM26-T5
)
DNA methyltransferase inhibitor
anti-TIM3 monoclonal antibody
antimetabolite
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
Warning
: preg_match(): Compilation failed: missing closing parenthesis at offset 43 in
/home/topowadl/articanz.org/table.php
on line
440
ACTRN12621000223831
Haem
Phase 2
Recruiting
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (
PREACH-M--(PREACH-M
)
DNA methyltransferase inhibitor
anti-GM-CSF monoclonal antibody
antimetabolite
vitamin C drug class
Chronic myelomonocytic leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
ACTRN12610001031055
Haem
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML
DNA methyltransferase inhibitor
antimetabolite
mTORC1 inhibitor
Acute myeloid leukaemia
ACTRN12610000641099
Haem
Phase 2
Recruiting
A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia (
AZA-E
)
DNA methyltransferase inhibitor
antimetabolite
thrombopoietin receptor agonist
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (22)
Not yet recruiting (6)
Recruitment Country and State
NSW (17)
VIC (17)
WA (16)
QLD (11)
SA (9)
NZ (3)
ACT (2)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (9)
Phase 2 (4)
Phase 3 (8)
Phase 4 (1)
Trial Type
Haem (26)
Advanced (1)
Paed (1)
Cancer Therapy Class
DNA methyltransferase
100%
Bcl2
57%
KMT2A
14%
menin-MLL1
11%
menin
11%
cytidine deaminase
11%
IDH1
7%
IDH1 R132
7%
FLT3
7%
ALK
4%
RET
4%
ISR
4%
multikinase
4%
CDC7
4%
FAK
4%
CD33
4%
AURKA
4%
AURKB
4%
Aurora
4%
BRD4
4%
TIM3
4%
GM-CSF
4%
mTOR
4%
mTORC1
4%
Facility
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (10)
3004 - Melbourne, Southbank - Alfred Health (8)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (8)
3168 - Clayton - Monash Medical Centre (7)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
6000 - Perth - Royal Perth Hospital (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
2139 - Concord - Concord Repatriation General Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3066 - Epping - Northern Hospital (4)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
2217 - Kogarah - St George Hospital (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
6009 - Nedlands - Hollywood Private Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
2605 - Garran - The Canberra Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2500 - Wollongong - Wollongong Private Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
6009 - Nedlands - One Clinical Research (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4812 - Townsville - Townsville University Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
4350 - Toowoomba - Toowoomba Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2500 - Wollongong - Wollongong Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Acute myeloid leukaemia
Myeloid leukaemia
Myeloproliferative neoplasm
Myelodysplastic syndrome
Myelodysplastic/Myeloproliferative disease
Chronic myelomonocytic leukaemia
Solid tumour
Lung cancer
Lymphoma
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy